The incomplete understanding of the relationship between phenotype and cancer genotype limits the efficacy of genome-based cancer therapeutic matching. This gap can be bridged by functional testing of live patient tumor tissues, which holds immense potential to increase the predictive power of current stratification biomarkers and reduce the dismal >90% failure rate of oncology clinical trials. MISO Chip, a Montreal-based startup, offers a groundbreaking solution by leveraging 3D tumor ...